Department of Urology, SUNY Upstate Medical University, Syracuse, NY.
Department of Urology, SUNY Upstate Medical University, Syracuse, NY.
Urology. 2021 Oct;156:31-36. doi: 10.1016/j.urology.2021.04.033. Epub 2021 May 4.
To examine the utility of a modified spermatic cord block (MSCB) that targets known contributors to refractory chronic scrotal content pain (CSCP) at predicting postoperative pain relief following a microscopic spermatic cord denervation (MSCD).
A MSCB was performed in all patients with refractory CSCP. This was performed by injecting anesthetic circumferentially around the vas deferens and over the external ring. Patients with >50% pain reduction were offered MSCD. Baseline, post-block, and postoperative pain was assessed. Age, prior groin surgery, and post-block pain free period were recorded. A multivariate linear regression model was used to determine predictors of surgical success.
Fifty-two patients underwent a MSCB. Forty-six (88%) had an adequate response and underwent MSCD. All patients saw improvement in pain postoperatively with an average reduction of 80% (4 < 50%; 7 50-69%; 35 ≥ 70%). On multivariate linear regression analysis, pain reduction following MSCD was an independent predictor of postoperative improvement (P < 0.001). No other factors, including post-block pain free period or prior surgery predicted success.
The described MSCB can be utilized as an independent predictor of success following MSCD. Post-block pain free period was not associated with postoperative pain level. The MSCB may help identify candidates for MSCD that would be missed with the traditional block.
探讨改良精索阻滞(MSCB)在预测显微镜精索去神经(MSCD)术后疼痛缓解方面的应用,该阻滞针对难治性慢性阴囊内容物疼痛(CSCP)的已知原因。
所有难治性 CSCP 患者均行 MSCB。通过在输精管周围和外环上注射麻醉剂来进行。对疼痛减轻>50%的患者提供 MSCD。评估基线、阻滞后和术后疼痛。记录年龄、腹股沟手术史和阻滞后无疼痛期。采用多元线性回归模型确定手术成功的预测因素。
52 例患者接受了 MSCB。46 例(88%)有足够的反应并接受了 MSCD。所有患者术后疼痛均有改善,平均减轻 80%(4 < 50%;7 50-69%;35 ≥ 70%)。多元线性回归分析显示,MSCD 后疼痛减轻是术后改善的独立预测因素(P < 0.001)。其他因素,包括阻滞后无疼痛期或既往手术均与手术成功率无关。
所描述的 MSCB 可作为 MSCD 后成功的独立预测因素。阻滞后无疼痛期与术后疼痛水平无关。MSCB 可能有助于识别传统阻滞可能遗漏的 MSCD 候选者。